Trial Information

Summary: Asthma Study

Official title:
A phase IIIB multicenter, randomized, double-blind, placebo-controlled study of XolairŽ in subjects with moderate to severe persistent asthma who are inadequately controlled with high-dose inhaled corticosteroids and long-acting beta-agonists.

Condition being studied:
Persistent Asthma

Inclusion/Exclusion Criteria:
You may qualify to participate in this research trial if you:

  • are between the ages of 12 and 75
  • have a history of moderate to severe asthma for at least one year requiring use of corticosteroids
  • have asthma symptoms and have required prednisone in the past year

If you qualify for this research trial you may receive:

  • Study medication at no cost
  • Compensation for time and travel
  • Study related medical treatment at no cost

For more information,

Contact:

Medical Research Associates of Central New York
5229 Witz Drive
North Syracuse, NY 13212
Telephone: 315-701-9599
Fax: 315-701-9598
Email:

Profile Page: Medical Research Associates of Central New York, North Syracuse, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:29:51 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA